The money will help the Franklin Lakes, N.J.-based company boost its production capacity by 50 percent and produce more than 12 million test kits per month by next February, it said.
“Making COVID-19 diagnostic tests widely available is critical to expanding rapid detection of COVID-19 infections and mitigating the impact of the disease by identifying affected patients, quickly quarantining infectious individuals and tracing their contacts,” said Dave Hickey, Beckton, Dickinson & Co.’s president of integrated diagnostic solutions. “This investment will bolster our U.S. manufacturing capabilities, helping us quickly scale our production of point-of-care COVID-19 tests to ensure we have a robust supply for our U.S. customers.”
Read the full news release here.
More articles on supply chain:
FDA puts hand sanitizers on import alert, adds more to do-not-use list
Freight, shipping companies say they’re not ready to distribute COVID-19 vaccine
See-through masks in high demand as COVID-19 cases rise
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
